Analysts See $-0.43 EPS for Nektar Therapeutics (NKTR)

April 22, 2018 - By Ellis Scott

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It turned negative, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported.
Ubs Asset Americas owns 220,894 shares. Tocqueville Asset Mngmt Lp has 0.21% invested in Nektar Therapeutics (NASDAQ:NKTR) for 308,062 shares. Financial Architects Incorporated has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). University Of Notre Dame Du Lac invested in 66,200 shares. Ameritas Investment Prtn Inc owns 12,690 shares or 0.03% of their US portfolio. Advisory Research Inc holds 36,507 shares. 169,785 are held by State Common Retirement Fund. Moreover, Raymond James And Assoc has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR). Profund Advsr Ltd Liability reported 80,937 shares stake. Conning accumulated 5,100 shares or 0.01% of the stock. Leisure owns 9,582 shares. Pointstate Ltd Partnership invested in 2.28% or 3.93 million shares. The New York-based Morgan Stanley has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). 156,517 were reported by Granahan Inv Management Ma. Assetmark Inc has 51 shares.

Since December 13, 2017, it had 0 insider buys, and 18 insider sales for $68.39 million activity. KUEBLER CHRISTOPHER A sold 30,000 shares worth $1.76 million. The insider CHESS ROBERT sold 25,000 shares worth $2.30M. The insider Doberstein Stephen K sold $14.89M. The insider Hora Maninder sold $3.03M. 30,000 shares were sold by GREER R SCOTT, worth $2.77M. 3,477 shares were sold by Labrucherie Gil M, worth $288,382 on Friday, February 16.

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.43 EPS on May, 8.They anticipate $0.01 EPS change or 2.38 % from last quarter’s $-0.42 EPS. After having $-0.14 EPS previously, Nektar Therapeutics’s analysts see 207.14 % EPS growth. The stock decreased 4.37% or $3.94 during the last trading session, reaching $86.21. About 2.72 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 22, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 12 analyst reports since November 7, 2017 according to SRatingsIntel. Roth Capital maintained it with “Buy” rating and $45.0 target in Monday, November 13 report. Mizuho maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, March 29. Mizuho has “Buy” rating and $8900 target. On Friday, April 6 the stock rating was maintained by Mizuho with “Buy”. The stock has “Buy” rating by Cowen & Co on Monday, April 9. The firm has “Buy” rating by Canaccord Genuity given on Thursday, November 9. The rating was maintained by Jefferies on Wednesday, November 8 with “Buy”. The rating was maintained by PiperJaffray on Friday, April 13 with “Overweight”. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, January 10 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, April 2.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $13.87 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: